Genomic Valley Biotech logo

Genomic Valley Biotech

539206 BSE
₹43.63 2.07 (4.98%)
Market Cap
₹13.26 Cr
P/E
1454.33

Genomic Valley Biotech (GVBL) share price was ₹43.63 at the 28 Oct 2026 close; market capitalisation ₹13.26 Cr; P/E (TTM) 1454.33; sector Healthcare. The share price rose 46.6% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue was ₹0.04 Cr, against ₹0.09 Cr a year earlier and net profit was ₹0.01 Cr, against ₹0.02 Cr a year earlier (compared with Jun 2025). Promoters held 46.06% of Genomic Valley Biotech in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 44/100 (Weak) as of 28 Oct 2026.

Close 28 Oct 2026 ₹43.63 +13.86 +46.56% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹13.26 Cr
P/E (TTM)
1,454.33
EBITDA
₹5.00 L
Return on Equity
9.13%
Debt to Equity
0
Book Value
₹12.85
EPS (TTM)
₹0.03
52W High
₹43.63
52W Low
₹20.10

Price-based figures as of 28 Oct 2026, 16:30 IST · EPS basis: Standalone · TTM

Peer Comparison

Healthcare › Biotechnology

Anthem Biosciences
₹832.1581.1946,894 Cr15.410.24%19.45%26.78%2,161 Cr576 Cr
Advanced Enzyme Tech
₹259.7517.532,887 Cr1.782.05%10.31%13.58%800 Cr172 Cr
CCME Global
₹31.93—144 Cr3.610.00%-0.35%0.87%0 Cr-1 Cr
Shree Ganesh Biotech
₹0.44—18 Cr0.270.00%0.59%0.81%7 Cr-0 Cr
Genomic Valley Biotech (this company)
₹43.631,454.3313 Cr3.400.00%9.13%11.32%0 Cr0 Cr
Median 5 companies₹43.6381.19144 Cr3.400.00%9.13%11.32%7 Cr0 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.

Tapetide Score

Data-driven rating, 0–100. How it works →

As of 2026-10-28
v2.0.0
44 Weak
Overall score
Data confidence 95/100

Category scores

Quality Poor 34
Returns, margins, earnings quality 22%
Valuation Poor 25
Cheap vs sector & own history 24%
Growth Poor 1
Sales & profit trajectory 9%
Financial Health Strong 86
Solvency, leverage, coverage 9%
Momentum Strong 99
Trend strength, vol-adjusted 12%
Ownership Average 50
FII/DII/promoter flows 24%

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company is almost debt free.

Weaknesses

6
  • Stock is trading at 2.51 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of 5.15% over past five years.
  • Company has a low return on equity of 3.68% over last 3 years.
  • Company has high debtors of 3,136 days.
  • Promoter holding has decreased over last 3 years: -20.3%

Technical Indicators

Oscillators

BearishNeutralBullish

Bearish

Bearish
5
Neutral
2
Bullish
2

Overall

BearishNeutralBullish

Bullish

Bearish
5
Neutral
2
Bullish
12

Moving Averages

BearishNeutralBullish

Bullish

Bearish
0
Neutral
0
Bullish
10

Growth Rate

Revenue Growth
-66.25% lower than 3Y

change over 1 year

Net Income Growth
-92.5% lower than 3Y

change over 1 year

Cash Flow Change
250%

change over 1 year

EBITDA Margin Change
-64.61%

change over 1 year Operating margin 50% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
0.06
0.07
0.04
0
0.16
0.21
0.22
0.26
0.09
0.09
0.05
0.04
0.04
Expenses
0.03
0.05
0.02
0.04
0.03
0.07
0.06
0.26
0.06
0.09
0.04
0.04
0.02
Operating Profit
0.03
0.02
0.02
-0.04
0.13
0.14
0.16
0
0.03
0
0.01
0
0.02
OPM %
50%
28.57%
50%
—
81.25%
66.67%
72.73%
0%
33.33%
0%
20%
0%
50%
Other Income
0
0
0
0
0
0.01
0
0
0
0
0
0
0
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
0
PBT
0.03
0.02
0.02
-0.04
0.13
0.15
0.16
0
0.03
0
0.01
0
0.02
Tax %
0%
0%
0%
0%
0%
0%
0%
—
0%
—
0%
—
0%
Net Profit
0.03
0.02
0.02
-0.04
0.13
0.15
0.16
-0.08
0.02
0
0.01
-0.01
0.01
EPS (₹)
0.1
0.07
0.07
-0.13
0.43
0.49
0.52
-0.26
0.07
0
0.03
-0.03
0.03
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
0.03
0.11
0.44
0.59
0.99
0.85
0.21
0.07
2.72
0.17
0.84
0.27
0.22
Expenses
0.07
0.54
0.48
0.49
0.57
0.3
0.34
0.45
1.84
0.15
0.4
0.23
0.19
Operating Profit
-0.04
-0.43
-0.04
0.1
0.42
0.55
-0.13
-0.38
0.88
0.02
0.44
0.04
0.03
OPM %
-133.33%
-390.91%
-9.09%
16.95%
42.42%
64.71%
-61.9%
-542.86%
32.35%
11.76%
52.38%
14.81%
13.64%
Other Income
0.07
0.16
0.01
0.03
0.01
0.01
0
0.5
-0.22
0
0
0
0
Interest
0.03
0.02
0
0
0
0.18
0.18
0.04
0
0
0
0
0
Depreciation
0.01
0.05
0.04
0.08
0.19
0.18
0.19
0.08
0.01
0
0
0
0
PBT
-0.01
-0.34
-0.07
0.05
0.24
0.2
-0.5
0
0.65
0.02
0.44
0.04
0.03
Tax %
0%
-2.94%
0%
40%
0%
-40%
12%
—
0%
0%
20.45%
25%
—
Net Profit
-0.01
-0.33
-0.07
0.03
0.23
0.29
-0.56
-0.01
0.65
0.02
0.36
0.03
0.01
EPS (₹)
-0.03
-1.08
-0.23
0.1
0.75
0.95
-1.83
-0.03
2.13
0.07
1.18
0.1
0.03
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
3.05
3.05
3.05
3.05
3.05
3.05
3.05
3.05
3.05
3.05
3.05
3.05
Reserves
1.84
1.51
1.44
1.47
1.71
1.99
1.43
-0.18
0.47
0.49
0.84
0.87
Borrowings
0.75
0.75
0.75
0.75
1.48
1.48
1.55
0
0
0
0
0
Other Liabilities
0.8
0.73
0.78
1.41
0.94
1.49
1.59
0.92
0.9
0.79
0.47
0.33
Total Liabilities
6.44
6.04
6.02
6.68
7.18
8.01
7.62
3.79
4.42
4.33
4.36
4.25
Fixed Assets
3.15
3.18
3.63
4.12
4.31
4.47
5.86
1.75
0
0
0.01
0
CWIP
0
0
0
0.38
0.49
0.49
0.49
0
0
0
0
0
Investments
0.55
0.11
0
0
0
0
0
0
0
0.02
0
0
Other Assets
2.74
2.75
2.39
2.18
2.38
3.05
1.27
2.04
4.42
4.31
4.35
4.25
Total Assets
6.44
6.04
6.02
6.68
7.18
8.01
7.62
3.79
4.42
4.33
4.36
4.25
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0.09
-0.69
0.35
0.87
-1.04
0.44
1.48
-2.13
-0.78
-0.02
0.03
-0.02
Investing
-0.65
0.53
-0.31
-0.91
0.37
-0.47
-1.58
3.67
1.52
-0.02
0.01
0
Financing
0
0
0
0
0.73
0
0.07
-1.55
-0.7
0
0
0
Net Cash Flow
-0.56
-0.16
0.04
-0.04
0.06
-0.04
-0.03
-0.01
0.04
-0.04
0.04
-0.02
Free Cash Flow
-0.05
-0.77
-0.15
-0.07
-0.68
-0.04
-0.1
3.22
0.7
-0.02
0.02
-0.02
CFO/OP
-225
160
-875
870
-248
80
-1,138
561
-89
-100
27
-25
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
0
0
0
12.37
22.12
42.94
104
0
298
5,432
960
3,136
Inventory Days
0
0
—
—
—
—
0
—
0
—
487
—
Days Payable
—
—
—
—
—
—
—
—
—
—
17.38
—
Cash Conversion Cycle
0
0
0
12.37
22.12
42.94
104
0
298
5,432
1,430
3,136
Working Capital Days
-8,882
-1,659
-514
-804
55.3
-176
-1,251
4,849
221
4,530
917
3,177
ROCE %
0.35%
-5.84%
-0.57%
0.57%
4.17%
5.96%
-5.1%
-8.54%
28.48%
0.57%
11.84%
1.02%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Genomic Valley Biotech insights

56 extracted metrics + investor summaries across FY12–FY27.

Shareholding Pattern

Public50.91%Others3.02%Promot.46.06%As ofSep 2026

Documents

Frequently Asked Questions about Genomic Valley Biotech

What does Genomic Valley Biotech Ltd do?
Incorporated in 2001, Genomic Valley Biotech Ltd is in the business of Horticultural and Agricultural products, and is also adding activities in Human Genomic[1]
Where is Genomic Valley Biotech Ltd (GVBL) listed?
Genomic Valley Biotech Ltd trades under code 539206 on the BSE.
Which sector does Genomic Valley Biotech Ltd belong to?
Genomic Valley Biotech Ltd is classified under the Healthcare sector, in the Biotechnology industry.
What is the market capitalisation of Genomic Valley Biotech Ltd?
Genomic Valley Biotech Ltd has a market capitalisation of ₹13.26 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Genomic Valley Biotech Ltd?
Genomic Valley Biotech Ltd trades at a PE ratio of 1454.33 as of 28 Oct 2026, on earnings per share of ₹0.03, against a book value of ₹12.85 per share.
What is the 52-week high and low of Genomic Valley Biotech Ltd?
Over the last 52 weeks Genomic Valley Biotech Ltd has traded between ₹20.1 and ₹43.63 as of 28 Oct 2026.
What is the Return on Equity (ROE) of Genomic Valley Biotech Ltd?
Genomic Valley Biotech Ltd reported a return on equity of 9.13%. Its debt-to-equity ratio is 0.00.

Company Information

Incorporated in 2001, Genomic Valley Biotech Ltd is in the business of Horticultural and Agricultural products, and is also adding activities in Human Genomic[1]

Website genomicvalley.com
Listed 2020-01-14
Face Value ₹ 10
Shares Outstanding 30,40,047

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/539206.md for Genomic Valley Biotech Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month